Radiation Oncology Model: What You Need to Know

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

FDA approves Merck's Keytruda for certain patients with metastatic colorectal cancer a month after study results were presented at ASCO.

A new report outlines the sharp cost increase associated with a NSCLC drug’s move from second-line to first-line treatment, and suggests payers work with manufacturers to address treatment pricing.

Chemotherapy may be the “boomer” to millennial-esque new cancer treatments, but there is a reason the old standard became that way, and isn’t likely to be replaced anytime soon.

There are a lot of ideas about ways to increase the value of cancer care, but personalized treatments may be the most significant and immediate.  

A holistic approach provides value and creates plans that support the wide-ranging needs of cancer patients and their families.